Skip to sources
Time Machine

Pharmacists

Scrub through 216years of this role's history, from when it first emerged, through every wave of technology that reshaped it, to the cited projections for where it's heading next.

2026drag to travel through time
18251850187519001925195019752000now
Country
2026
Known today as Pharmacist — Pharm.D. (BLS SOC 29-1051)
US Employment
322K
OEWS is a point-in-time survey snapshot, not a continuous time series; BLS advises against using it for year-over-year trend comparison.
Median Annual Wage
$140,910
≈ $137,297 in 2024 dollars
Each dot is a cited figure over time; the dotted line only links them (values between aren't measured). Hollow dots are estimates.
Tools of the era

The tools that defined the work

Select an era to see how it reshaped the work.

  • Mortar, pestle, and US Pharmacopeia — the compounding era

    For the first 130 years of the modern American pharmacy, the pharmacist's primary tool was the mortar and pestle. A prescription from a physician was a formula — "take these crude ingredients, combine them in these proportions, and prepare them in this form." The pharmacist was part chemist, part craftsperson: grinding, dissolving, filtering, and shaping medications from raw botanical and chemical materials. The 1820 US Pharmacopeia gave this craft its scientific foundation, establishing standard formulations for 217 drugs and the analytical tests required to verify their quality. The APhA (1852) added professional organization; state licensing laws (beginning with Louisiana, 1869) added legal exclusivity. By 1890 the pharmacist was a licensed professional with a defined body of knowledge, a regulated scope of practice, and a set of tools — the mortar, the prescription balance, the dispensing vials — that would not fundamentally change until the 1950s.

    Effect on the work

    Compounding was skilled labor that resisted mechanization. A pharmacist who could prepare a stable suppository or an accurate ophthalmic solution was doing work that required years of training and could not easily be delegated. This skill premium supported wages throughout the compounding era.

    Work toolChanging equipment
  • FDCA (1938) + commercial pharmaceutical manufacturing — the dispensing transition

    The Federal Food, Drug, and Cosmetic Act of 1938 gave the FDA authority to require safety demonstrations before drug marketing, accelerating the pharmaceutical industry's shift to large-scale commercial production. The 1943 mass production of penicillin — and the subsequent wave of antibiotics, antihypertensives, and other synthetic drugs — made it economically irrational for individual pharmacists to compound what a factory in New Jersey could produce for pennies. By the early 1950s, as the Wikipedia article on compounding notes, "the majority of dispensed drugs came directly from the large pharmaceutical companies." Pharmacists went from mixing drugs to counting and dispensing pre-packaged tablets. The 1951 Durham-Humphrey Amendment — co-sponsored by Senator Hubert Humphrey and Representative Carl Durham, both pharmacists — formally divided drugs into prescription and OTC categories, requiring licensed dispensing for the former and establishing the refill-authorization system that became a pharmacist's daily operational framework.

    Effect on the work

    The transition from compounding to dispensing deskilled the manual preparation work but created a new clinical role: the pharmacist as drug-interaction expert, patient counselor, and licensed gatekeeper to controlled medications. Prescription volume grew dramatically as new drug categories emerged; employment grew with it.

    Work toolChanging equipment
  • Medicare / Medicaid (1965) + retail pharmacy computer systems — the volume era

    Medicare and Medicaid (signed July 30, 1965) were the largest single drivers of retail prescription volume in US history. The elderly and low-income populations who had previously ration-filled prescriptions due to cost now had coverage; prescription volume at retail pharmacies roughly doubled over the following decade. Simultaneously, the retail pharmacy chains — Walgreens, Rite Aid (founded 1962), CVS (founded 1963 as Consumer Value Stores) — were expanding aggressively into the suburban shopping-center model, creating the high-volume, 200-prescription-per-day pharmacy that would define the profession for the next 40 years. Early prescription dispensing computer systems (Rx-30, QS/1, and others entering the market in the 1980s) automated label printing, drug-interaction checking, and insurance billing, allowing pharmacists to process higher volumes without proportional headcount increases.

    Effect on the work

    The 1965-1995 era was the golden age of retail pharmacy employment growth: prescription volume grew from approximately 1.5 billion annual fills in 1970 to nearly 2.7 billion by 1994 as baby boomers aged and new chronic-disease drug categories expanded. Pharmacist wages rose steadily; the profession attracted applicants with competitive undergraduate records who might otherwise have pursued medicine.

    Work toolChanging equipment
  • ScriptPro / Parata robotic dispensing + automatic dispensing cabinets

    ScriptPro LLC was founded in 1994 and commercialized the first pharmacy robotic dispensing system for high-volume retail environments. The ScriptPro SP 200 (and successors) could count, cap, and label over 200 prescription fills per hour using a carousel of drug canisters and a robotic arm — matching the throughput of a skilled pharmacy technician without breaks, errors, or overtime. Parata Systems developed competing automated dispensing technology for both retail and institutional pharmacy settings. By the 2000s, every major chain pharmacy (CVS, Walgreens, Rite Aid) was deploying robotic dispensing in high-volume locations, primarily to reduce technician labor costs rather than pharmacist hours directly. The clinical argument used to justify keeping pharmacists while automating counting: the pharmacist's value was in verification, patient counseling, and drug-interaction review — not pill counting. For hospital pharmacy, Pyxis automated dispensing cabinets (introduced in the 1990s) moved medication storage to the point of care on nursing units, allowing pharmacists to spend more time on clinical review rather than cart-filling.

    Effect on the work

    Robotic dispensing did not reduce pharmacist headcount in the short term — prescription volumes were growing fast enough to absorb the productivity gain. The long-term effect was to concentrate retail pharmacy into higher-volume locations (which could justify robotic investment), accelerating chain consolidation and the closure of independent pharmacies that could not compete on price.

    Work toolChanging equipment
  • Medicare Part D (2006) + Medication Therapy Management — the clinical-services era

    The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Medicare Part D — the largest expansion of prescription drug benefits in US history, effective January 2006. Part D did two things for pharmacists: it drove an enormous increase in covered prescription fills for Medicare beneficiaries (adding 43 million new covered patients over time), and it mandated that Part D plans include Medication Therapy Management (MTM) programs. MTM authorized pharmacists to conduct comprehensive medication reviews, identify drug-therapy problems, and bill Medicare directly for the service — the first time pharmacists had a widely reimbursed clinical service distinct from dispensing. By 2014, CMS required all Part D plans to include MTM programs, and enrolled patients with multiple chronic conditions (typically 3+ conditions and 8+ medications) were eligible for annual comprehensive reviews. MTM transformed the policy argument for clinical pharmacy: rather than justifying pharmacist employment by prescription volume alone, health systems and insurers now had a billing framework for pharmacist cognitive services.

    Effect on the work

    MTM created new employment categories — ambulatory care pharmacists, integrated health-system clinical pharmacists, Medicare Part D MTM specialists — that partially offset retail employment pressures from automation and chain closures. The clinical track offered better work conditions and grew through the 2010s, while retail pharmacy employment stagnated.

    Work toolChanging equipment
  • COVID-19 vaccination programs — pharmacists as mass immunizers

    The COVID-19 pandemic activated a long-latent legal authority: since 2006, most states had granted pharmacists the right to administer vaccinations, but retail vaccination had been primarily seasonal flu shots. The federal government's emergency authorization under the PREP Act (Public Readiness and Emergency Preparedness Act) allowed pharmacists to administer COVID-19 vaccines to patients of all ages, transforming retail pharmacies into primary vaccine administration sites. At peak vaccination demand (spring 2021), pharmacies were administering millions of COVID doses per week — CVS alone administered over 30 million COVID vaccines by mid-2021. For pharmacists, this was a moment of extraordinary professional visibility: they were the accessible, no-appointment-needed front line of the largest mass vaccination campaign in American history. The immunization authority demonstrated that pharmacist scope could expand rapidly when political will aligned with public health need.

    Effect on the work

    Vaccination-driven demand created temporary staffing pressure and reinforced the clinical-pharmacist narrative — that pharmacist value is highest in direct patient care, not behind a counting machine. The authority was expected to persist post-pandemic, adding a durable immunization dimension to retail pharmacist scope.

    Work toolChanging equipment
  • Chain implosion + central-fill automation — the restructuring era

    Three simultaneous forces reshaped retail pharmacy after 2021. First, the mass closure wave: CVS announced 900 US store closures in November 2021 (approximately 10% of its footprint), Walgreens announced up to 2,150 closures (25% of stores) in June 2024, and Rite Aid — which had operated 5,059 stores at its 2008 peak — filed for Chapter 11 bankruptcy in October 2023 and liquidated completely by October 2025. Second, central-fill automation: all three chains had been shifting high-volume chronic-medication fills to central automated facilities (essentially warehouses of robotic dispensing equipment), routing routine refills away from retail pharmacies and leaving retail locations to handle acute prescriptions and clinical services. Third, mail-order and PBM-owned pharmacies (CVS Caremark, Express Scripts) continued capturing the chronic-refill market from retail. The combined effect: fewer retail pharmacy locations, each serving higher patient volumes, with more automation and fewer staff per prescription filled.

    Effect on the work

    The chain closures created a paradox: retail pharmacist employment pressure increased even as BLS projected overall growth, because the new jobs (health-system clinical pharmacy, MTM specialists, ambulatory care) required different credentials and were located in different settings than the retail jobs being eliminated. Pharmacists in rural areas and communities that lost their only drugstore faced the hardest transitions.

    Work toolChanging equipment
Projection cone · present → 2034

What credible sources project

Scrub the slider past now to anchor each scenario on the scrubber. The spread is the range of futures credible sources project for this role.

Employment outlook
Projected change in the number of people doing this work.
McKinsey Global Institute (2023)
2030
+8%
McKinsey's July 2023 "Generative AI and the Future of Work in America" projects healthcare as the sector with the largest absolute job gains through 2030, driven by aging-population demand growth that exceeds productivity gains from AI tools. Pharmacists fall within the healthcare professionals category that McKinsey projects as net-growing. The +8% estimate approximates the McKinsey optimistic scenario where clinical-pharmacy expansion (MTM, telepharmacy, integrated health-system practice) absorbs workers displaced from retail by automation and chain closures. McKinsey explicitly models gen AI as augmenting pharmacist cognitive tasks (drug-interaction review, MTM documentation) rather than substituting for the licensed practitioner.
BLS National Employment Matrix 2024-34
2034
+5%
BLS Employment Projections 2024-34 cycle. National Employment Matrix reports base employment of 335,100 (2024) and projected employment of 350,500 (2034), a change of +15,400 (+4.6%, rounded to +5% in OOH). Described as "Faster than average." The retail-trade sector (37.3% of employment) is projected to decline slightly (-1.6%), while health care and social assistance settings are projected to grow, reflecting the clinical-pharmacy shift. BLS cites aging-population prescription volume and MTM clinical-services expansion as primary growth drivers.
O*NET / BLS OOH 2024
2034
+5%
BLS Occupational Outlook Handbook 2024 edition, drawing on the same Employment Projections data. OOH projects 14,200 annual average job openings for pharmacists through 2034, combining new-job growth and replacement needs (retirement and occupational transfer). The OOH framing explicitly notes the shift toward clinical and health-system settings while retail pharmacy contracts. The +5% figure masks significant structural redistribution: retail loses, ambulatory/health-system gains.
AI task exposure
Share of the role’s tasks that researchers estimate AI can do. This is a measure of task exposure, not a forecast of jobs lost.
Frey & Osborne (2013)
2033
50%
of tasks
Gaussian-process classifier on O*NET task features. Frey & Osborne assigned Pharmacists a probability of computerization of approximately 0.58 (58%) — placing pharmacy in the high-risk segment of their 702-occupation analysis. The risk drivers were the high proportion of routine information-processing tasks (verifying prescriptions, checking insurance eligibility, dispensing counted medications) that F&O assessed as susceptible to software automation. The -50% figure represents the implied employment ceiling if the F&O probability were realized. In practice, the profession has grown modestly since 2013, suggesting F&O overestimated robotic-dispensing substitution speed and underweighted the clinical-pharmacy regulatory and scope-of-practice dynamics that have sustained demand. Treat as the pessimistic tail of the projection cone.
Eloundou et al. — "GPTs are GPTs" (2023)
2028
10%
of tasks
GPT-4 task-by-task LLM-exposure labeling on O*NET tasks for pharmacists. Pharmacists score moderately on LLM exposure because significant portions of the role involve information processing, patient counseling (which an LLM could partially draft), and drug-interaction checking (which software already handles). The physical dispensing, licensed verification, and patient-contact components score lower on exposure. The -10% estimate represents the range of tasks where LLM augmentation could reduce pharmacist time-on-task substantially without eliminating the role — comparable to how EHR-integrated drug-interaction checking reduced the cognitive load of manual cross-referencing without eliminating pharmacist review. The clinical-services expansion (MTM, immunization) is the structural counter to LLM displacement.
Today, in this role

What's shifting in the work right now

The historical view above shows how this role has moved. This is the present-day detail: which AI tools are picking up which tasks, where the edge still is, and the natural directions this work can grow.

What's changing in your day

Three parts of your work where AI is already doing real lifting, and what stays yours.

AI is sitting alongside you hereManage prior authorization workflows — processing prior auth requests for specialty medications through AI-assisted platforms (Surescripts Prior Authorization Automation, Latent Health integrated with Epic), reviewing automated determinations for clinical accuracy, escalating complex cases requiring additional clinical documentation, and counseling patients on formulary alternatives when automated PA is denied.

Manage prior authorization workflows — processing prior auth requests for specialty medications through AI-assisted platforms (Surescripts Prior Authorization Automation, Latent Health integrated with Epic), reviewing automated determinations for clinical accuracy, escalating complex cases requiring additional clinical documentation, and counseling patients on formulary alternatives when automated PA is denied.[7],[10]

Where your edge is

Prior auth automation is cutting routine PA approval time to 18 seconds (Surescripts 2025) and specialty PA throughput by 50%+ at Ochsner Health — the administrative burden that historically consumed pharmacist time is shrinking fast. Your focus shifts to the exception queue: complex, non-standard requests where clinical nuance determines coverage, and to counseling patients on therapeutic alternatives when denial is final. Build expertise in specialty drug coverage policies and payer-specific clinical criteria to own the high-stakes escalations.

AI is sitting alongside you hereVerify and approve prescriptions routed for final pharmacist sign-off from robotic dispensing systems (Omnicell XR2, Walgreens micro-fulfillment robots) — reviewing barcode-verified fill accuracy logs, confirming patient identity and allergy flags in Epic or MEDITECH, releasing the verified prescription for dispensing, and flagging any dosage or substitution anomalies that require pharmacist intervention before the medication leaves the pharmacy.

Verify and approve prescriptions routed for final pharmacist sign-off from robotic dispensing systems (Omnicell XR2, Walgreens micro-fulfillment robots) — reviewing barcode-verified fill accuracy logs, confirming patient identity and allergy flags in Epic or MEDITECH, releasing the verified prescription for dispensing, and flagging any dosage or substitution anomalies that require pharmacist intervention before the medication leaves the pharmacy.[5],[9],[1]

Where your edge is

Robotic dispensing systems now handle the physical fill and barcode verification — your value in this task is clinical judgment on the exception queue: catching allergy conflicts, therapeutic duplication, and dosage anomalies the system flagged. Focus on building fluency with your pharmacy's specific dispenser exception-management interface and develop a systematic review protocol for the high-risk flags (narrow therapeutic index drugs, weight-based dosing) where a miss has patient safety consequences.

AI is sitting alongside you hereManage pharmacy inventory and automated dispensing cabinet replenishment — using Omnicell OmniSphere cloud analytics to monitor automated dispensing cabinet (ADC) stock levels, generating AI-recommended reorder quantities, reconciling controlled substance diversion reports, and coordinating 340B drug pricing compliance for eligible health system purchases.

Manage pharmacy inventory and automated dispensing cabinet replenishment — using Omnicell OmniSphere cloud analytics to monitor automated dispensing cabinet (ADC) stock levels, generating AI-recommended reorder quantities, reconciling controlled substance diversion reports, and coordinating 340B drug pricing compliance for eligible health system purchases.[6],[1]

Where your edge is

Inventory and replenishment are increasingly automated — the Omnicell OmniSphere platform cuts restocking workflow time by 70% per Holzer Regional Medical Center data. Your defensible role here is controlled substance diversion monitoring (requires human accountability and DEA compliance) and 340B compliance oversight — these are regulatory functions with legal consequences that the inventory platform surfaces but a pharmacist must validate and sign off on.

Where this role is heading

Natural next steps for someone with your foundation: not exits, evolutions.

A direction you could grow

Medical and Health Services Managers

Pharmacists who develop operational, regulatory, and financial expertise naturally transition into pharmacy director, director of pharmacy operations, or health system pharmacy leadership roles. As automated dispensing systems absorb routine fill volume, the pharmacy director role — vendor governance, formulary management, 340B program oversight, controlled substance compliance, and AI-tool strategy — becomes more strategically valuable. BLS projects Medical and Health Services Managers at +29% growth 2024-2034, one of the fastest-growing management occupations. Pharmacy directors at hospital systems command salaries of $160,000–$220,000+. The PharmD credential plus operational experience maps directly to the credentialing requirement.

What you'd add
· Healthcare operations management: staffing models, departmental P&L, productivity benchmarking against ASHP pharmacy staffing standards
· 340B drug pricing compliance: covered entity eligibility, split-billing software, OPA audit readiness
What it takesSome new skills to pick up
Share this year
Drops anyone you send it to straight into 2026.
Preview card
Part of Healthcare · see all 69roles →
Different role?

See the same long-arc view for your own profession.

Browse the directory by industry, or search by title or SOC code. New roles ship every few weeks. Every profile cites every claim.

Browse all roles

The data behind this timeline

On record since1820
Latest tracked employment321,970 (US, 2025)
Latest median pay$140,910 (2025)
Outlook+5% by 2034 (BLS National Employment Matrix 2024-34)
View all 27 cited data points
YearUS employmentMedian annual paySource
190056,000n/aCENSUS-DECENNIAL
194088,000n/aESTIMATE
1960112,000n/aESTIMATE
2000217,000n/aBLS-OEWS
2003215,030$80,530BLS-OEWS
2004222,960$84,900BLS-OEWS
2005229,740$89,820BLS-OEWS
2006239,920$94,520BLS-OEWS
2007253,110$100,480BLS-OEWS
2008266,410$106,410BLS-OEWS
2009267,860$109,180BLS-OEWS
2010268,030$113,600BLS-OEWS, ESTIMATE
2011272,320$113,390BLS-OEWS
2012281,560$116,670BLS-OEWS
2013287,420$119,280BLS-OEWS
2014297,100$120,950BLS-OEWS
2015295,620$121,500BLS-OEWS
2016305,510$122,230BLS-OEWS
2017309,330$124,170BLS-OEWS
2018309,550$126,120BLS-OEWS
2019311,200$128,090BLS-OEWS
2020315,470$128,710BLS-OEWS
2021312,550$128,570BLS-OEWS
2022325,480$132,750BLS-OEWS
2023331,700$136,030BLS-OEWS
2024335,100$137,480BLS-OEWS
2025321,970$140,910BLS-OEWS
Embed this timeline on your site

Free for any site. Paste this where the timeline should appear; it stays interactive, every datapoint stays cited, and it sets no cookies on your page. How embedding works

<iframe src="https://futurehistory.earth/embed/29-1051"
  width="100%" height="430" style="border:0"
  title="Pharmacists, a Future History timeline"
  loading="lazy"></iframe>

See all roles in Healthcare